Medical Science
| Open Access |
DOI: Clinical Case and Literature Analytical Review of Metaplastic Breast Cancer
Yusupbekov Abrorbek Ahmedjanovich , Prof. MD, Deputy Director, Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan Almuradova Dilbar Muradovna , PhD, Associate professor of Department of Oncology, oncohematology and radiation oncology. Tashkent State Medical University, Tashkent, Uzbekistan Ikromova Guli Ne’matovna , 2nd Year master's student, Department of Oncology, Oncogematology and Radiation Oncology Tashkent State Medical University, Tashkent, Uzbekistan Umarova Zilola Abdullayevna , 2nd year master's student, Department of Oncology, Oncogematology and Radiation Oncology Tashkent State Medical University, Tashkent, Uzbekistan Malikova Laylo Nodirovna , 2nd year master's student, Department of Oncology, Oncogematology and Radiation Oncology. Tashkent State Medical University, Tashkent, UzbekistanAbstract
Basis: metaplastic mammary cancer is a rare type of tumor with high aggressiveness of mammary gland cancer, and skin scarring (wound formation) causes much more complexity in clinical practice, dramatically reducing the patient's quality of life. Today, there are no standard treatment guidelines for the treatment of metaplastic breast cancer, and this skin-related condition associated with breast tumors limits treatment options. Diagnosis: in this article we will provide information on the effectiveness of metaplastic mammary gland cancer and skin scarring in the treatment of a patient with exudation(detachment) and acute odor based on his immunogystochemical and molecular-genetic profile. Intervention: in a lawsuit with docetaxel + carboplatin AUK 5.5, the patient showed severe pain in the patient after taking Course 3, increased bleeding marks in the injured area, no change in the tumor was observed when evaluated. When treated by changing the scheme to CAP (Endoxan, doxorubicin, carboplatin) +bevasizumab(based on the molecular-genetic examination profile), there was a complete end to the skin wound and a decrease in the size of the tumor.In the next stage, the patient was treated with radical mastectomy and radiation therapy. Result: The patient's quality of life improved after complex treatment, the patient's condition improved, and the disease regressed. Conclusion: This study showed that the treatment of metastatic breast cancer should be based on immunohistochemical and molecular-genetic profiling, and that this approach yields good results.
Keywords
Metastatic breast cancer, Case report, bevacizumab
References
Adams S, Othus M, Patel S, et al. Metaplastic breast cancers and triple-negative breast cancers of no special type: systematic review and meta-analysis. Breast Cancer Research and Treatment. 2014; 146(3): 519–529. (PubMed)
Altaf F, Mokhtar GA, Emam E, Bokhary RY, Bin Mahfouz N, Al Amoudi S. Metaplastic carcinoma of the breast: an immunohistochemical study. Diagnostic Pathology. 2014;9:139. (7-9)
Dasgupta J, et al. Histopathological spectrum of metaplastic carcinoma of the breast. Seminars in Diagnostic Pathology. 2025; 42(1): 45–54. Thieme Medical Publishers (Thieme Connect).
El Zein D, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer. Clinical Breast Cancer. 2017; 17(5): 382–391. (Elsevier, PubMed) (7-9)
El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer. Clinical Breast Cancer. 2017;17(5):382–391.(7-9)
Gao Y, Li S, Wang J, et al. Multimodal treatment for giant breast cancer with severe skin ulceration in elderly patients. World Journal of Surgical Oncology. 2018;16:64.(15)
Gullo G, Zuradelli M, Sclafani F, Santoro A. Long-term survival of HER2-positive metastatic breast cancer treated with trastuzumab. Tumori Journal. 2012;98(2):214–219.(14)
Holland R, van Haelst UJ. Mammary carcinoma with osteoclast-like giant cells and other variants. Cancer. 1984; 53(9): 1963–1973. (JEMDS / IMSEAR)
Li J, Chen Z, Su K, Zeng J. Advanced breast cancer with skin ulceration successfully treated with chemotherapy and targeted therapy: a case report. Oncology Letters. 2016;12(2):1097–1100.(13)
Meng X, Yang Z, Tang X, Mu L, Cao X, Wang X. Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast. Oncology Letters. 2017; 14(2): 1971–1978. Spandidos Publications.
Munawar A, et al. Triple-negative metaplastic breast carcinoma: association of EGFR expression with prognosis. Journal of Cancer Research and Therapeutics. 2020; 16(4): 842–848. (PubMed)
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases. Annals of Surgical Oncology. 2007;14(1):166–173.
Rakha EA, Tan PH, Shaaban A, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Breast Cancer Research and Treatment. 2015; 153(2): 337–347. (PubMed)
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Annals of Oncology. 1999;10(4):413–419. (4-6)
Reddy TP, Rosato RR, Li X, et al. Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple-negative breast cancer. Breast Cancer Research. 2020; 22(1): 94. (PubMed) (4-9)
Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020;22(1):121. doi:10.1186/s13058-020-01353-z. Available from: https://link.springer.com/article/10.1186/s13058-020-01353-z
Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate?Annals of Surgical Oncology. 2011;18(1):94–103.(4-6)
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: I. Matrix-producing carcinoma. Human Pathology. 1989;20(7):628–635.(3)
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: II. Spindle cell carcinoma. Human Pathology. 1989;20(8):732–740.(3)
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: III. Carcinosarcoma. Human Pathology. 1989;20(8):741–749.(3)
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: IV. Squamous cell carcinoma of ductal origin. Human Pathology. 1990;21(1):21–27.(3)
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Human Pathology. 1990;21(11):1142–1150.(3)
Wu J, Zhang L, Wu J, et al. Paclitaxel exacerbates skin injury in mice by inhibiting keratinocyte proliferation. Toxicol Lett. 2014;229(1):108–115. doi:10.1016/j.toxlet.2014.05.012.(12)
World Health Organization (WHO). Breast cancer fact sheet. Geneva: WHO; 2025 [cited 2025 Dec 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer (1)
Wu J, Zhang L, Wu J, et al. Paclitaxel exacerbates skin injury in mice by inhibiting keratinocyte proliferation. Toxicol Lett. 2014;229(1):108–115. doi:10.1016/j.toxlet.2014.05.012.
Xie J, Li Z, Zhang Y, et al. Population-based analysis of metaplastic breast cancer incidence and mortality. J Clin Oncol Res. 2023;15(4):215–223. Available from: https://www.sciencedirect.com/science/article/pii/S1015958423014653
27.Yamaguchi R, Tanaka M, et al. Metaplastic carcinoma of the breast: an immunohistochemical study. Diagn Pathol. 2014;9:139. doi:10.1186/1746-1596-9-139. Available from: https://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-9-139
Zhang Y, Yang SH, Guo XL, et al. Paclitaxel induces skin ulceration and delays wound healing. International Journal of Molecular Medicine. 2013;31(4):907–914. doi:10.3892/ijmm.2013.1295. (11)
Download and View Statistics
Copyright License
Copyright (c) 2026 Yusupbekov Abrorbek Ahmedjanovich, Almuradova Dilbar Muradovna, Ikromova Guli Ne’matovna, Umarova Zilola Abdullayevna, Malikova Laylo Nodirovna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.